Steven T Chen, Yevgeniy R Semenov, Allireza Alloo, Daniel Q Bach, Allison Betof Warner, Amina Bougrine, Leeann Burton, Laura C Cappelli, Mariana Castells, Justine Cohen, Anna K Dewan, Riley Fadden, Lauren Guggina, Aparna Hegde, Victor Huang, Douglas B Johnson, Benjamin Kaffenberger, Daniela Kroshinsky, Shawn Kwatra, Bernice Kwong, Mario E Lacouture, Cecilia Larocca, Jonathan Leventhal, Alina Markova, Jon McDunn, Meghan J Mooradian, Jarushka Naidoo, Jennifer Choi, Vinod Nambudiri, Caroline A Nelson, Anisha B Patel, Julia Pimkina, Johnathan Rine, Krista M Rubin, Maxwell Sauder, Sheila Shaigany, Afreen Shariff, Ryan J Sullivan, Leyre Zubiri, Kerry L Reynolds, Nicole R LeBoeuf
With an increasing number of patients eligible for immune checkpoint inhibitors, the incidence of immune-related adverse events (irAEs) is on the rise. Dermatologic immune-related adverse events (D-irAEs) are the most common and earliest to manifest, often with important downstream consequences for the patient. Current guidelines lack clarity in terms of diagnostic criteria for D-irAEs. The goal of this project is to better define D-irAE for the purposes of identification, diagnosis, and future study of this important group of diseases...
April 10, 2024: Journal for Immunotherapy of Cancer